Current challenges in the pathophysiology, diagnosis, and treatment of paroxysmal movement disorders.
Cécile DelormeCamille GironDavid BendetowiczAurélie MéneretLouise-Laure MarianiEmmanuel RozePublished in: Expert review of neurotherapeutics (2020)
Treatment of genetic causes of paroxysmal movement disorders is evolving towards precision medicine with targeted gene-specific therapy. Alteration of the cerebellar output and modulation of the striatal cAMP turnover offer new perspectives for experimental therapeutics, at least for paroxysmal movement disorders due to selected causes. Further characterization of cell-specific molecular pathways or network dysfunctions that are critically involved in the pathogenesis of paroxysmal movement disorders will likely result in the identification of new biomarkers and testing of innovative-targeted therapeutics.